Results 221 to 230 of about 116,711 (370)

Ischemic stroke in a patient with EGFR‐mutated non–small‐cell lung cancer after treatment with ramucirumab

open access: yesThoracic Cancer, Volume 13, Issue 23, Page 3412-3414, December 2022., 2022
A case of a non–small‐cell lung cancer patient harboring epidermal growth factor receptor mutation with multiple brain metastasis experienced a new ischemic stroke after treatment with ramucirumab. Abstract Vascular endothelial growth factor (VEGF) inhibitors have been widely investigated in the last 10 years, with particular attention paid to their ...
Guo‐Yu Chen   +2 more
wiley   +1 more source

Epidermolysis bullosa for primary care providers: A practical review

open access: yesJournal of General and Family Medicine, EarlyView.
Abstract Epidermolysis bullosa (EB) is a group of genetic skin diseases, which manifest as fragile skin and blistering in addition to many extracutaneous conditions. Pediatricians and primary care providers play an integral role in managing these patients with multifaceted care needs.
Kennedy Sparling   +9 more
wiley   +1 more source

Anlotinib plus chemotherapy for T790M‐negative EGFR‐mutant non‐sqNSCLC resistant to TKIs: A multicenter phase 1b/2 trial

open access: yesThoracic Cancer, Volume 13, Issue 24, Page 3496-3503, December 2022., 2022
Patients with T790M‐negative EGFR‐mutant advanced NSCLC received anlotinib plus platinum‐based chemotherapy after resistance to first‐ or second‐generation EGFR TKIs. The maximum tolerated dose (MTD) of anlotinib was 12 mg, and the median PFS was 5.75 (95% CI: 4.37–7.52) months.
Juan Li   +7 more
wiley   +1 more source

Hyperlipemia in renal disease [PDF]

open access: yes, 1945
Thesis (M.D.)--Boston ...
Franklin, William
core  

The efficacy of PDE5 inhibitors in diabetic patients

open access: yesAndrology, Volume 11, Issue 2, Page 245-256, February 2023., 2023
Abstract Background Phosphodiesterase 5 inhibitors (PDE5i), since their introduction in the late 1990s, have proven their efficacy in treating several conditions, predominantly pulmonary hypertension and erectile dysfunction where they remain the first‐line therapeutic option.
Agnieszka Swiecicka
wiley   +1 more source

Home - About - Disclaimer - Privacy